Trial Profile
Comparison of satisfaction in personalized medicine with hypotensive drug between elderly hypertensive Patients-voice and physician of voice
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2017
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/azelnidipine (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 05 Jan 2017 Status changed from active, no longer recruiting to completed.
- 25 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 23 Oct 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network- Japan record.